Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000078290 | SCV000110130 | pathogenic | not provided | 2012-12-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000822976 | SCV000963808 | pathogenic | Fabry disease | 2023-09-04 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects GLA function (PMID: 19941952). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLA protein function. ClinVar contains an entry for this variant (Variation ID: 92561). This missense change has been observed in individual(s) with Fabry disease (PMID: 19941952, 20367968, 27560961, 28756410; Invitae). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 216 of the GLA protein (p.Tyr216Cys). |
Genome- |
RCV000822976 | SCV002054424 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |